The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, +78

Nature Cancer

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

Pamela N. Münster, Rahul Aggarwal, David S. Hong, +15

Clinical Cancer Research

Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors

Jürgen Wolf, Patricia LoRusso, R.D. Camidge, +14

Cancer Research

PathologyAdvanced Solid TumorsEscalation StudyTumor BiologyFgf Receptors +14

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer

Ruud van der Noll, Serena Marchetti, Neeltje Steeghs, +6

British Journal of Cancer

AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies

Aurelius Omlin, Robert J. Jones, Ruud van der Noll, +22

Investigational New Drugs

UrologyOncologyGenitourinary CancerMedicineHormonal Receptor +5

Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors .

Fabrice André, Malcolm Ranson, Emma Dean, +10

Cancer Research

Fgfr Gene AmplificationOncologyMedicineCancer Cell BiologyPathology +12

Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors.

Ruud van der Noll, Joo Ern Ang, Agnes Jager, +11

Journal of Clinical Oncology

Brca1/2 MutationMedicineContinuous OTablet FormulationsPharmacology +13

A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors

Stephen Leong, Rebecca A. Moss, Daniel W. Bowles, +9

The Oncologist

Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826).

Pamela N. Münster, Ruud van der Noll, Emile E. Voest, +17

Journal of Clinical Oncology

Mg. Dose-limiting ToxicitySteady StatePhosphatidylinositol 3-KinaseMedicineMetronomic Therapy +12

Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors .

Udai Banerji, Malcolm Ranson, Jan H.M. Schellens, +14

Cancer Research

PathologyPharmacotherapyAdvanced Solid TumorsPd BiomarkersTumor Biology +14